Top

Published in:

01-06-2010 | Letter

Open versus laparoscopic versus robotic gastrectomy for cancer: need for comparative-effectiveness quality

Authors: G. Glantzounis, D. Ziogas, G. Baltogiannis

Published in: Surgical Endoscopy | Issue 6/2010

Excerpt

New technologies and medical devices may improve both health care and research toward the development of new drugs. But they are a major driver of increases in U.S. health care expenditures, which have grown by an estimated 71% since 2000 [1]. In an economic crisis, cost effectiveness for new therapies (e.g., robotic surgery) should be considered. …

Stafford RS, Wagner TH, Lavori PW (2009) New, but not improved? Incorporating comp arative-effectiveness information into FDA labeling. N Engl J Med 361(13):1230–1233CrossRef

Garber AM, Tunis SR (2009) Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 360:1925–1927CrossRefPubMed

Liakakos T, Roukos DH (2008) More controversy than ever: challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15:956–960CrossRefPubMed

Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMed

Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16:795–798CrossRefPubMed

Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9:828–830CrossRefPubMed

Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7:719–726CrossRefPubMed

Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11:727–730CrossRefPubMed

Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom, and why. Ann R Coll Surg Engl 80:16–24PubMed

10.

Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253–255CrossRefPubMed

11.

Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3:115–125CrossRefPubMed

12.

Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129CrossRefPubMed

13.

Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84:1602–1609CrossRefPubMed

14.

Kim MC, Heo GU, Jung GJ (2009) Robotic gastrectomy for gastric cancer: surgical techniques and clinical merits. Surg Endosc. August 18 (Epub ahead of print)

15.

Dolgin E (2009) Collins sets out his vision for the NIH. Nature 460:939CrossRefPubMed

16.

Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249:1067–1068CrossRefPubMed

17.

Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16:1771–1782CrossRefPubMed

18.

Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9:227–229CrossRefPubMed

19.

Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9:217–221CrossRefPubMed

20.

Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392CrossRefPubMed

21.

Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721CrossRefPubMed

22.

Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27:1337–1338CrossRefPubMed

23.

Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362–1363CrossRefPubMed

24.

Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775CrossRefPubMed

25.

Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358:1636CrossRefPubMed

26.

Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556CrossRefPubMed

27.

Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9:1–6CrossRefPubMed

28.

Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715CrossRefPubMed

29.

Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16:77–773

30.

Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMed

31.

Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995CrossRefPubMed

32.

Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416 CrossRefPubMed

33.

Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMed

34.

Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350 CrossRefPubMed

35.

Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMed

36.

Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRef

Title: Open versus laparoscopic versus robotic gastrectomy for cancer: need for comparative-effectiveness quality
Authors: G. Glantzounis
D. Ziogas
G. Baltogiannis
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 6/2010
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-009-0790-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Open versus laparoscopic versus robotic gastrectomy for cancer: need for comparative-effectiveness quality

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2010

Laparoscopic adrenalectomy for large unilateral pheochromocytoma: experience in a large academic medical center

Increased mRNA expression of epidermal growth factor receptor, human epidermal receptor, and survivin in human gastric cancer after the surgical stress of laparotomy versus carbon dioxide pneumoperitoneum in a murine model

News and notices

Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer

True single-port appendectomy: first experience with the “puppeteer technique”

Is the laparoscopic approach to colectomy safe for the morbidly obese?